Seeking Alpha
 

Synthetic Biologics, Inc. (SYN)

- NYSEMKT
  • Mon, Mar. 16, 8:26 AM
    • Synthetic Biologics (SYN -3.7%) FY14 results: Revenues: $0; R&D Expense: $14.5M (+123.1%); SG&A: $6M (+3.4%); Operating Loss: ($20.5M) (-66.7%); Net Loss: ($19.8M) (-61.0%); Loss Per Share: ($0.32) (-18.5%); Quick Assets: $17.5M (+19.9%).
    • No guidance given.
    | Comment!
  • Mon, Mar. 16, 7:02 AM
    | 1 Comment
  • Nov. 14, 2014, 8:12 AM
    • Synthetic Biologics (SYN -2.7%) Q3 results: Revenues: $0; R&D Expense: $3.7M (+146.7%); G&A: $1.2M (-36.8%); Net Loss: ($4.9M) (-44.1%); Loss Per Share: ($0.08) (unch); Quick Assets: $3.4M (-76.7%).
    • No guidance given.
    | Comment!
  • Nov. 14, 2014, 6:59 AM
    • Synthetic Biologics (NYSEMKT:SYN): Q3 EPS of -$0.08 misses by $0.03.
    • Press Release
    | Comment!
  • Aug. 14, 2014, 7:20 AM
    • Synthetic Biologics (NYSEMKT:SYN) Q2 results: Revenues: $0; Operating Expenses: $4.7M (+89.0%); Net Loss: ($4.6M) (-82.5%); Loss Per Share: ($0.08) (-33.3%); Quick Assets: $7.8M (-46.4%).
    • No financial guidance given.
    | Comment!
  • Aug. 14, 2014, 7:00 AM
    • Synthetic Biologics (NYSEMKT:SYN): Q2 EPS of -$0.08 misses by $0.01.
    • Press Release
    | Comment!
  • May. 15, 2014, 10:48 AM
    • Shares of nano cap Synthetic Biologics (SYN +17.2%) jump on a 40% increase in volume in response to its Q1 financial report and business update.
    • Operating loss: ($3.8M) (-72.7%); cash & equiv: $11.2M (-23.2%).
    • The company will conduct a 28-day bridging toxicology study on its lead anti-infective product candidate, SYN-004 next month followed by an IND application. A Phase 1a/1b trial should begin in 2H 2014 with preliminary top-line results by year end. A Phase 2 trial will follow in 1H 2015.
    • A Phase 1 trial for its anti-pertussis product candidate, SYN-005, should begin in Q1 2015 with top-line data available after 90 days. A Phase 2 trial will follow with top-line results expected by 2H 2015. The company intends to request Orphan Drug Designation for SYN-005 for the treatment of pertussis (whooping cough).
    • Expect an additional capital raise in the near future.
    | 2 Comments
  • May. 15, 2014, 7:34 AM
    | Comment!
  • Nov. 14, 2013, 7:26 AM
    • Synthetic Biologics (SYN): Q3 EPS of -$0.08. (PR)
    | Comment!
  • Aug. 14, 2013, 7:24 AM
    • Synthetic Biologics (SYN): Q2 EPS of -$0.06. (PR)
    | Comment!
  • May. 15, 2013, 7:15 AM
    Synthetic Biologics (SYN): Q1 EPS of -$0.05 in-line. (PR)
    | Comment!
  • Apr. 16, 2013, 3:05 PM
    Synthetic Biologics (SYN -1.2%) slips after reporting its year-end financials this morning, reiterating its focus on strengthening its infectious disease portfolio. The company says it's raised capital this year that includes $10.1M in net proceeds from the sale of about 6.8M shares. Other income was $15K, compared to an expense of $1.7M for the same period in 2011.
    | Comment!
Visit Seeking Alpha's
SYN vs. ETF Alternatives
Company Description
Synthetic Biologics Inc is a biotechnology company focused on the development of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and other diseases.
Sector: Healthcare
Industry: Biotechnology
Country: United States